Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | flavodoxin family protein | 0.0117 | 0.4038 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0117 | 0.4038 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0117 | 0.4038 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0072 | 0.0972 | 0.0972 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0117 | 0.4038 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0117 | 0.4038 | 0.3396 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0117 | 0.4038 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0059 | 0.0061 | 0.0061 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0072 | 0.0972 | 0.2145 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0058 | 0 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0117 | 0.4038 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0117 | 0.4038 | 0.3396 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0117 | 0.4038 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0117 | 0.4038 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0117 | 0.4038 | 0.5 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0104 | 0.3127 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0104 | 0.3127 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.4038 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0117 | 0.4038 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0117 | 0.4038 | 0.3396 |
Brugia malayi | FAD binding domain containing protein | 0.0117 | 0.4038 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0117 | 0.4038 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0058 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0117 | 0.4038 | 0.4038 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0117 | 0.4038 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0117 | 0.4038 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0117 | 0.4038 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0117 | 0.4038 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0072 | 0.0972 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0117 | 0.4038 | 0.3396 |
Brugia malayi | FAD binding domain containing protein | 0.0072 | 0.0972 | 0.2145 |
Leishmania major | p450 reductase, putative | 0.0117 | 0.4038 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.